- Home
- TWO vs ZYME Comparison
TWO vs ZYME Comparison
Compare TWO & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWO
- ZYME
- Stock Information
- Founded
- TWO 2009
- ZYME 2003
- Country
- TWO United States
- ZYME United States
- Employees
- TWO N/A
- ZYME N/A
- Industry
- TWO Real Estate Investment Trusts
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- TWO Real Estate
- ZYME Health Care
- Exchange
- TWO Nasdaq
- ZYME Nasdaq
- Market Cap
- TWO 1.1B
- ZYME 968.5M
- IPO Year
- TWO 2009
- ZYME 2017
- Fundamental
- Price
- TWO $10.11
- ZYME $14.35
- Analyst Decision
- TWO Buy
- ZYME Buy
- Analyst Count
- TWO 9
- ZYME 7
- Target Price
- TWO $12.94
- ZYME $20.00
- AVG Volume (30 Days)
- TWO 2.1M
- ZYME 427.2K
- Earning Date
- TWO 07-28-2025
- ZYME 08-07-2025
- Dividend Yield
- TWO 15.45%
- ZYME N/A
- EPS Growth
- TWO N/A
- ZYME N/A
- EPS
- TWO N/A
- ZYME N/A
- Revenue
- TWO $257,735,000.00
- ZYME $122,867,000.00
- Revenue This Year
- TWO N/A
- ZYME $44.71
- Revenue Next Year
- TWO N/A
- ZYME $34.57
- P/E Ratio
- TWO N/A
- ZYME N/A
- Revenue Growth
- TWO N/A
- ZYME 95.94
- 52 Week Low
- TWO $9.67
- ZYME $9.03
- 52 Week High
- TWO $14.28
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- TWO 49.84
- ZYME 61.41
- Support Level
- TWO $9.73
- ZYME $11.51
- Resistance Level
- TWO $10.26
- ZYME $14.05
- Average True Range (ATR)
- TWO 0.20
- ZYME 0.61
- MACD
- TWO 0.04
- ZYME 0.07
- Stochastic Oscillator
- TWO 54.05
- ZYME 94.88
About TWO Two Harbors Investment Corp
Two Harbors Investment Corp is a real estate investment trust focused on investing in, financing, and managing residential mortgage-backed securities, or RMBS; residential mortgage loans; mortgage servicing rights; and commercial real estate. The majority of the company's investment portfolio is split between agency RMBS purchased from government-sponsored enterprises and nonagency RMBS. Two Harbors derives nearly all of its revenue in the form of interest income collected from its investments. The majority of this income is generated by available-for-sale securities, while residential mortgage loans held for investment in securitization trusts also contribute a sizable amount.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.